Annexin A1 expression in a pooled breast cancer series : association with tumor subtypes and prognosis

Show full item record



Permalink

http://hdl.handle.net/10138/164124

Citation

Sobral-Leite , M , Wesseling , J , Smit , V T H B M , Nevanlinna , H , van Miltenburg , M H , Sanders , J , Hofland , I , Blows , F M , Coulson , P , Patrycja , G , Schellens , J H M , Fagerholm , R , Heikkila , P , Aittomaki , K , Blomqvist , C , Provenzano , E , Ali , H R , Figueroa , J , Sherman , M , Lissowska , J , Mannermaa , A , Kataja , V , Kosma , V-M , Hartikainen , J M , Phillips , K-A , Couch , F J , Olson , J E , Vachon , C , Visscher , D , Brenner , H , Butterbach , K , Arndt , V , Holleczek , B , Hooning , M J , Hollestelle , A , Martens , J W M , van Deurzen , C H M , van de Water , B , Broeks , A , Chang-Claude , J , Chenevix-Trench , G , Easton , D F , Pharoah , P D P , Garcia-Closas , M , de Graauw , M , Schmidt , M K & kConFab AOCS Investigators 2015 , ' Annexin A1 expression in a pooled breast cancer series : association with tumor subtypes and prognosis ' BMC Medicine , vol. 13 , 156 . DOI: 10.1186/s12916-015-0392-6

Title: Annexin A1 expression in a pooled breast cancer series : association with tumor subtypes and prognosis
Author: Sobral-Leite, Marcelo; Wesseling, Jelle; Smit, Vincent T. H. B. M.; Nevanlinna, Heli; van Miltenburg, Martine H.; Sanders, Joyce; Hofland, Ingrid; Blows, Fiona M.; Coulson, Penny; Patrycja, Gazinska; Schellens, Jan H. M.; Fagerholm, Rainer; Heikkila, Paivi; Aittomaki, Kristiina; Blomqvist, Carl; Provenzano, Elena; Ali, Hamid Raza; Figueroa, Jonine; Sherman, Mark; Lissowska, Jolanta; Mannermaa, Arto; Kataja, Vesa; Kosma, Veli-Matti; Hartikainen, Jaana M.; Phillips, Kelly-Anne; Couch, Fergus J.; Olson, Janet E.; Vachon, Celine; Visscher, Daniel; Brenner, Hermann; Butterbach, Katja; Arndt, Volker; Holleczek, Bernd; Hooning, Maartje J.; Hollestelle, Antoinette; Martens, John W. M.; van Deurzen, Carolien H. M.; van de Water, Bob; Broeks, Annegien; Chang-Claude, Jenny; Chenevix-Trench, Georgia; Easton, Douglas F.; Pharoah, Paul D. P.; Garcia-Closas, Montserrat; de Graauw, Marjo; Schmidt, Marjanka K.; kConFab AOCS Investigators
Contributor: University of Helsinki, Department of Obstetrics and Gynegology
University of Helsinki, Dep. of Medical Genetics (Haartman Institute) (-2009)
University of Helsinki, Department of Pathology
University of Helsinki, Department of Medical and Clinical Genetics
University of Helsinki, Department of Oncology
Date: 2015-07-02
Language: eng
Number of pages: 11
Belongs to series: BMC Medicine
ISSN: 1741-7015
URI: http://hdl.handle.net/10138/164124
Abstract: Background: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. Methods: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. Results: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45). Conclusions: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
Subject: Breast cancer
Annexin A1
BRCA1 and BRCA2 mutations
GROWTH-FACTOR
PROTEIN-KINASE
CELLS
PHOSPHORYLATION
CHEMOTHERAPY
METASTASIS
SURVIVAL
COMPLEX
DIFFERENTIATION
ADENOCARCINOMA
3122 Cancers
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s12916_015_0392_6.pdf 1.827Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record